Growth factors and diabetic retinopathy

Diabetes and Metabolism

Volumn 23, Issue 2, 1997, Pages 125-130

  Paques, M ^a   Massin, P ^b   Gaudric, A ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b NONE

Author keywords

Angiogenesis inhibitors; Diabetic retinopathy; Growth factors; Ischaemia; Neovascularization

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

DIABETIC RETINOPATHY; HUMAN; LASER COAGULATION; NEOVASCULARIZATION (PATHOLOGY); REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; GROWTH SUBSTANCES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030987103     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK, 1948, 68, 137-180.
2. Pepper MS, FN Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Comm, 1992, 189, 824-831.
3. Pierce EA, AR Foley ED, Aiello LP, Smith LE. Vascular Endothelial Growth Factor/Vascular Permeablity Factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA, 1995, 91, 905-909.
4. Danis R, Massicotte S, Boldt C. Preretinal and optic nerve head neovascularisation induced by photodynamic venous thombosis in domestic pigs. Arch Ophthalmol, 1993, 111, 539-543.
5. 5a Kador P, Wyman M, Ferris F. Diabetes-like proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol, 1995, 113, 352-354.
6. 5b Gaudric A, N'Guyen T, Moenner M, Glacet-Bernard A, Barritault D. Quantification of angiogenesis due to fibroblast growth factor in a modified rabbit corneal model. Ophthalmic Res, 1992, 24, 181-188.
7. Sivalingam A, KJ Brown GC, Benson WE, Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol, 1990, 108, 869-872.
8. Hanneken A, de Lutty G, Fox G, Schiffer S, Hjelmeland L. Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol, 1991, 109, 1005-1011.
9. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors : studies in diabetes with and without retinopathy. N Engl J Med, 1983, 309, 994-1007.
10. Arner P, Gjotterberg M, Skottner A. Circulating IGF-1 in type 1 diabetic patients with retinopathy. Diabetologica, 1989, 32, 753-758.
11. Dills D, Klein R, Klein B, Davis M. Is insulin-like factor associated with diabetic retinopathy ? Diabetes, 1990, 3, 191-195.
12. Hyers SL, Brooks RA, Burrin JM, Kohner EM. A two year follow-up study of IGF-1 in diabetics with retinopathy. Metabolism, 1989, 38, 586-589.
13. Grant M, Fitzgerald C, Merimee TJ. Insulin-like growth factor in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes, 1986, 35, 416-420.
14. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding protein 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest, 1993, 92, 2620-2625.
15. Bach L. Insulin-like growth factors and diabetes. Diabetes/metabolism Review, 1992, 8, 229-257.
16. Stavri GT HY Zachary IC, Breier G, et al. Hypoxia and platelet-derived growth factor synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett, 1995, 358, 311-315.
17. Robbins SG, Mixon RN, Wilson DJ, et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 1994, 35, 3649-3663.
18. Favard C, Dorey C, Praloran V, Plouet J. Purification and biological properties of vasculotropin, a new angiogenic cytokine. Biol Cell, 1991, 73, 1-6.
19. Hata Y, Ishibashi T, Inomata H, Ueno H, Sueishi K. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch, 1995, 426, 479-486.
20. Plouet J. Regulations of vasculotropin/vascular endothelial growth factor bioavailability. Horm Res, 1994, 42, 14-19.
21. Shweiki D, IA Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992, 359, 842-845.
22. Dvorak HF, Detmar M, Dvorak AM. Vascular Permeablity Factor/Vascular Endothelial Growth Factor, microvascular hyper-permeability, and angiogenesis. Am J Pathol, 1995, 146, 1029-1039.
23. Frank RN. On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology, 1991, 98, 586-593.
24. Miller JW, Adamis AP, Shima DT et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol, 1994, 145, 574-584.
25. Adamis A, Bernal MT, D'Amico D, Folkman J, Yeo T-K, Yeo K-T. Increased Vascular Endothelial Growth Factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol, 1994, 118, 445-450.
26. Aiello L, Arrigg P, Keyt B, Jampel H, et al. Vascular Endothelial Growth Factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl J Med, 1994, 131, 1480-1487.
27. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of VEGF mRNA and VEGF-like activity in proliferative diabetic retinopathy. Arch Ophthalmol, 1994, 112, 1476-1480.
28. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch ophthalmol, 1996, 114, 66-71.
29. Barinaga M. Shedding light on diabetic retinopathy. Science, 1995, 267, 452-453.
30. Klagsburn M. VEGF/VPS: The angiogenesis factor found ? Current Biology, 1993, 3, 699-702.
31. Frank RN. Vascular endothelial growth factor. Its role in retinal vascular proliferative diseases. N Engl J Med 1994, 331, 1519-1520.
32. Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol, 1976, 81, 383-396.
33. Yomshimura N, Matsumoto M, Shimizu H, Mandai M, Hata Y, Ishibashi T. Photocoagulated human retinal pigment epithelial cells produce an inhibitor of vascular endothelial cell proliferation. Invest Ophthalmol Vis Sci, 1995, 36, 1686-1691.
34. 33a Fan T-P, Bicknell R. Controlling the vasculature, angiogenesis, anti-angiogenesis and vascular targeting of gene therapy.Trends Pharmacol Sci, 1995, 16, 57-66.
35. 33b Mallet B, Viallettes B, Haroche S, Escoffier P et al. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metab,1992, 18, 438-444.
36. Antonelli-Orlidge A, Smith S, D'Amore P. An activated form af transforming growth factor -β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA, 1989, 86, 4544-4548.
37. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest, 1994, 94, 110-117.
38. Murata T, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular Endothelial Growth Factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res, 1995, 27, 48-52.